Drug Information

Drug (ID: DG00637) and It's Reported Resistant Information
Name
Carbamazepine
Synonyms
Carbamazepine; 298-46-4; Tegretol; Carbamazepen; 5H-Dibenzo[b,f]azepine-5-carboxamide; Finlepsin; Biston; 5H-Dibenz[b,f]azepine-5-carboxamide; Carbazepine; Tegretal; Equetro; Carbamezepine; Neurotol; Timonil; Epitol; Karbamazepin; Carbatrol; Stazepine; Telesmin; Lexin; Tegretol-Xr; benzo[b][1]benzazepine-11-carboxamide; Carbamazepin; Carbamazepinum; 5H-Dibenz(b,f)azepine-5-carboxamide; Carbamazepina; Amizepin; Bipotrol; Teril; Geigy 32883; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; Calepsin; Carnexiv; Sirtal; 5-Carbamoyl-5H-dibenz(b,f)azepine; 5-Carbamoyl-5H-dibenz[b,f]azepine; G 32883; G-32883; NSC 169864; MFCD00005073; CHEBI:3387; UNII-33CM23913M; CHEMBL108; 5-Carbamyldibenzo(b,f)azepine; MLS000069652; 5-Carbamoyldibenzo(b,f)azepine; CBZ; NSC169864; 33CM23913M; NSC-169864; NCGC00015234-11; CAS-298-46-4; SMR000058201; Stazepin; DSSTox_CID_2731; 2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene-2-carboxamide; DSSTox_RID_76704; DSSTox_GSID_22731; Carbamazepine Anhydrous; 5H-dibenzo[b,f]azepine-5-carboxamide;Oxcarbazepine IMpurity A; Carbelan; Tegretol Cr; Carbamazepinum [INN-Latin]; Carbamazepina [INN-Spanish]; SMR001227191; HSDB 3019; SR-01000000229; Carbatrol extended-release; EINECS 206-062-7; BRN 1246090; Karbelex; Neurotop; Trimonil; Neurotop retard; dibenzo[b,f]azepine-5-carboxamide; Tegretol (TN); Prestwick_104; Equetro (TN); Carbamazepine-[d2]; Carbamazepine, powder; Opera_ID_72; Spectrum_000096; Carbamazepine [USAN:USP:INN:BAN:JAN]; Prestwick0_000052; Prestwick1_000052; Prestwick2_000052; Prestwick3_000052; Spectrum2_000125; Spectrum3_000325; Spectrum4_000262; Spectrum5_000936; Carbamazepine (Carbatrol); Lopac-C-4024; ChemDiv1_018966; CBChromo1_000350; Epitope ID:174842; Iminostilbene-N-carboxamide; Carbamazepine-[13C,15N]; Lopac0_000292; Oprea1_790775; SCHEMBL21639; BSPBio_000203; BSPBio_001929; Carbamazepine extended release; KBioGR_000724; KBioSS_000516; MLS001055475; MLS001074172; MLS002548877; BIDD:GT0479; DivK1c_000388; DivK1c_003750; SPECTRUM1500159; SPBio_000170; SPBio_002124; BPBio1_000225; GTPL5339; ZINC4785; DTXSID4022731; SCHEMBL19838283; HMS501D10; HMS640O02; KBio1_000388; KBio2_000516; KBio2_003084; KBio2_005652; KBio3_001149; WLN: T C676 BNJ BVZ; AOB5783; Carbamazepine (JP17/USP/INN); CBZ;NSC 169864; dibenz[b,f]azepine-5-carboxamide; SPD-417; Carbamazepine, analytical standard; NINDS_000388; HMS1568K05; HMS1920I17; HMS2090M07; HMS2091O19; HMS2095K05; HMS2233G16; HMS3039K09; HMS3259B21; HMS3260L06; HMS3372J13; HMS3657G03; HMS3712K05; HMS3747E03; Pharmakon1600-01500159; ACT02606; BCP21380; HY-B0246; 5-Carbomoyl-5H-dibenzo(b,f)azepine; Tox21_110104; Tox21_202273; Tox21_300195; Tox21_500292; AC2074; BDBM50003659; CCG-38931; NSC755920; s1693; STK177357; STL453548; 11-benzo[b][1]benzazepinecarboxamide; 5H-Dibenz[b,f]azepine-5-carboxamine; Carbamazepine 1.0 mg/ml in Methanol; AKOS003235644; AKOS025397243; Tox21_110104_1; AC-9538; DB00564; KS-5146; LP00292; MCULE-9121567287; NC00679; NSC-755920; SDCCGSBI-0050280.P005; 5H-Dibenz[ b, f]azepine-5-carboxamide; CDS1_002710; IDI1_000388; 5H-Dibenzo[b,f]azepine-5-carboxamide #; NCGC00015234-01; NCGC00015234-02; NCGC00015234-03; NCGC00015234-04; NCGC00015234-05; NCGC00015234-06; NCGC00015234-07; NCGC00015234-08; NCGC00015234-09; NCGC00015234-10; NCGC00015234-12; NCGC00015234-13; NCGC00015234-14; NCGC00015234-15; NCGC00015234-16; NCGC00015234-18; NCGC00015234-19; NCGC00015234-33; NCGC00023877-03; NCGC00023877-04; NCGC00023877-05; NCGC00023877-06; NCGC00023877-07; NCGC00023877-08; NCGC00253982-01; NCGC00259822-01; NCGC00260977-01; BC166161; H495; SY002823; (z)-5h-dibenzo[b,f]azepine-5-carboxamide; SBI-0050280.P004; 5H-dibenzo[b,f]azepine-5-carboximidic acid; DB-047659; Dibenzo[b,f]azepine-5-carboxylic acid amide; EU-0100292; FT-0602927; FT-0696814; SW220141-1; BIM-0050280.0001; C 4024; C06868; Carbamazepine, meets USP testing specifications; D00252; 5H-Dibenz(b,f)azepine-5-carboxamide maleic acid; 5H-Dibenz(b,f)azepine-5-carboxamide oxalic acid; AB00051931-17; AB00051931-18; AB00051931_19; AB00051931_20; A820074; Q410412; carbamazepine host structure with maleic acid removed; carbamazepine host structure with oxalic acid removed; Q-200792; SR-01000000229-2; SR-01000000229-4; SR-01000000229-7; 5H-Dibenz(b,f)azepine-5-carboxamide DL-tartaric acid; BRD-K71799949-001-06-7; F0348-2551; Z2199879032; carbamazepine host structure with DL-tartaric acid removed; Dibenzo[b,f]azepine-5-carboxylic acid amide(Carbamazepine); carbamazepine host structure with 4-hydroxybenzoic acid removed; Carbamazepine, British Pharmacopoeia (BP) Reference Standard; Carbamazepine, European Pharmacopoeia (EP) Reference Standard; Carbamazepine, United States Pharmacopeia (USP) Reference Standard; Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material; N6W
    Click to Show/Hide
Indication
In total 4 Indication(s)
Epilepsy [ICD-11: 8A60]
Approved
[1]
Epilepsy [ICD-11: 8A60]
Approved
[1]
Gastric adenocarcinoma [ICD-11: 2B72]
Approved
[1]
Type-1 diabetes [ICD-11: 5A10]
Approved
[1]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (2 diseases)
Epilepsy [ICD-11: 8A60]
[2]
Trigeminal neuralgia [ICD-11: 8B82]
[3]
Target Sodium channel unspecific (NaC) NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C15H12N2O
IsoSMILES
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
InChI
1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
InChIKey
FFGPTBGBLSHEPO-UHFFFAOYSA-N
PubChem CID
2554
ChEBI ID
CHEBI:3387
TTD Drug ID
D04MSM
VARIDT ID
DR00395
INTEDE ID
DR0270
DrugBank ID
DB00564
Type(s) of Resistant Mechanism of This Drug
  IDUE: Irregularity in Drug Uptake and Drug Efflux
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-08: Nervous system diseases
Click to Show/Hide the Resistance Disease of This Class
Epilepsy [ICD-11: 8A60]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Irregularity in Drug Uptake and Drug Efflux (IDUE) Click to Show/Hide
Key Molecule: Multidrug resistance protein 1 (ABCB1) [2]
Molecule Alteration SNP
rs1128503
 Molecule Info 
Resistant Disease Epilepsy [ICD-11: 8A60.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
Mechanism Description ABCB1 polymorphisms were previously demonstrated to be associated with the metabolism and resistance of carbamazepine (CBZ) in epilepsy. ABCB1 rs1045642 and rs2032582 polymorphisms were associated with CBZ metabolism for epilepsy, and rs1128503 was related to carbamazepine resistance.
Genetic epileptic syndromes [ICD-11: 8A61]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Potassium inwardly rectifying channel subfamily J member 10 (KCNJ10) [1]
Molecule Alteration SNP
rs12402969 C+ Genotypes CC+CT
 Molecule Info 
Sensitive Disease Genetic generalized epilepsies [ICD-11: 8A61.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 Genotyping assay
Mechanism Description By analyzing the association between KCNJ10 polymorphisms and anti-epileptic drug efficacy of GGEs we found the frequency of rs12402969 C allele and CC+CT genotypes were higher in GGEs drug responsive patients than that in drug resistant patients
References
Ref 1 Common variants of KCNJ10 are associated with susceptibility and anti-epileptic drug resistance in Chinese genetic generalized epilepsies .PLoS One. 2015 Apr 13;10(4):e0124896. doi: 10.1371/journal.pone.0124896. eCollection 2015. 10.1371/journal.pone.0124896
Ref 2 Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis .Epilepsy Res. 2021 Nov;177:106785. doi: 10.1016/j.eplepsyres.2021.106785. Epub 2021 Oct 7. 10.1016/j.eplepsyres.2021.106785
Ref 3 Diabetes mellitus contributes to carbamazepine resistance in patient with trigeminal neuralgia .Neurosurg Rev. 2021 Apr;44(2):1119-1125. doi: 10.1007/s10143-020-01304-4. Epub 2020 Apr 24. 10.1007/s10143-020-01304-4

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.